The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients

Jin Su1, Chun-Xi Li1, Hai-Yue Liu2

  • 1Department of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical Universitygrid.284723.8, Guangzhou, China.

Microbiology Spectrum
|April 13, 2022
PubMed

Insights

Lung transplant recipients (LTRs) with infection or rejection show distinct airway microbiomes. Combining airway bacteria with clinical markers accurately differentiates between stable LTRs, infection, and acute rejection.

Area of Science:

  • Microbiology
  • Immunology
  • Transplantation Science

Background:

  • Lung transplantation (LT) survival is challenged by infection and rejection, the most frequent complications.
  • Differentiating post-LT infection from acute rejection is critical for recipient management and outcomes.

Purpose of the Study:

  • To investigate the association between airway microbiota composition and the occurrence of infection or rejection in lung transplant recipients (LTRs).
  • To evaluate the potential of airway microbiota, alongside clinical markers, in distinguishing between event-free, infection, and rejection states in LTRs.

Main Methods:

  • Collected 181 sputum samples from 59 LTRs categorized as event-free, infected, or experiencing rejection.
  • Analyzed airway microbiota using 16S rRNA gene sequencing.
  • Employed Linear Discriminant Analysis Effect Size (LEfSe) and Random Forest analyses to identify differential taxa and build predictive models.

Main Results:

  • Significant differences in airway microbial diversity and composition were observed among event-free, infection, and rejection groups.
  • Six bacterial genera (Actinomyces, Rothia, Abiotrophia, Neisseria, Prevotella, Leptotrichia) were enriched in LTRs with rejection.
  • A predictive model combining these genera with procalcitonin (PCT) and T-lymphocyte levels achieved high AUC values (0.895–0.919) for differentiating clinical states.

Conclusions:

  • The airway microbiota differs significantly between LTRs with infection and those with acute rejection.
  • Airway microbiota, particularly when integrated with PCT and T-lymphocyte levels, demonstrates strong predictive capability for differentiating clinical outcomes post-LT.
  • Airway microbiota serves as a promising biomarker for distinguishing between infection and acute rejection after lung transplantation.

Related Concept Videos